Varenicline and combination nicotine replacement therapy are the most effective pharmacotherapies for treating tobacco use

Evidence-Based Medicine

Volumn 18, Issue 6, 2013, Pages 212-213

  Ebbert, Jon O ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; MECAMYLAMINE; PLACEBO; RIMONABANT; VARENICLINE;

ABSENCE OF SIDE EFFECTS; BIRTH DEFECT; CLINICAL TRIAL; HUMAN; NICOTINE REPLACEMENT THERAPY; NOTE; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; TOBACCO USE;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BENZAZEPINES; BUPROPION; HUMANS; NICOTINIC AGONISTS; QUINOXALINES; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS;

EID: 84891951237     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/eb-2013-101462     Document Type: Note

References (3)

1. Giovino GA, Mirza SA, Samet JM, et al. Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys. Lancet 2012;380:668-79.
2. World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: World Health Organization, 2009. http://www.who. int/healthinfo/global-burden-disease/ GlobalHealthRisks-report-full.pdf (accessed 17 Jul 2013).
3. Food and Drug Administration. FDA drug safety communication: safety review update of Chantix (varenicline) and risk of neuropsychiatric adverse events. Silver Spring, MD: Food and Drug Administration, 2011. http://www.fda.gov/Drugs/DrugSafety/ucm276737.htm (accessed 17 Jul 2013).